Structure
LOXO-101, Inhibitor
LOXO-101
Purity
>98% (HPLC)
Synonyms
LOXO-101; ARRY470; ARRY-470; ARRY 470; LOXO 101; LOXO101; Larotrectinib; inhibitor
Purity/Purification
>98% (HPLC)
Suitability
DMSO: >=4.6mg/mL
Target
Trk Receptor
Receptor
Trk Receptor
Chemical Name
1-Pyrrolidinecarboxamide, N-[5-[(2R)-2-(2, 5-difluorophenyl)-1-pyrrolidinyl]pyrazolo[1, 5-a]pyrimidin-3-yl]-3-hydroxy-, (3S)
SMILES
C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F
Molecular Formula
C21H22F2N6O2
CAS Number
1223403-58-4
Preparation and Storage
Store at -20 degree C
Stability: >=2 years
Shipping: Ice Pack
Stability: >=2 years
Shipping: Ice Pack
Structure
Structure
Related Product Information for LOXO-101, inhibitor
LOXO-101 (ARRY-470, Larotrectinib) is potent, selective pan-TRK inhibitor with cellular IC50 of 2-20nM against TRKA, TRKB, and TRKC kinases; demonstrates excellent selectivity against a panel of 226 non-TRK kinases with one exception (TNK2 IC50=576nM); inhibits fusion oncoprotein and cellular proliferation in TRK-fusion-bearing human-derived cancer cell lines; markedly attenuates bone cancer pain and significantly blocks the ectopic sprouting of sensory nerve fibers and the formation of neuroma-like structures in the tumor bearing bone; inhibits tumor growth in vivo in TRK fusion-positive cancer models. Blood Cancer Phase 2 Clinical
Product Categories/Family for LOXO-101, inhibitor
References
1. Doebele RC, et al. Cancer Discov. 2015 Oct; 5 (10):1049-57.
2. Ghilardi JR, et al. Mol Pain. 2010 Dec 7; 6:87.
3. Vaishnavi A, et al. Nat Med. 2013 Nov; 19 (11):1469-1472.
4. Drilon A, et al. N Engl J Med. 2018 Feb 22; 378 (8):731-739.
2. Ghilardi JR, et al. Mol Pain. 2010 Dec 7; 6:87.
3. Vaishnavi A, et al. Nat Med. 2013 Nov; 19 (11):1469-1472.
4. Drilon A, et al. N Engl J Med. 2018 Feb 22; 378 (8):731-739.
Similar Products
Product Notes
The LOXO-101 (Catalog #AAA3600854) is an Inhibitor and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "LOXO-101, Inhibitor" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
